Cargando…

Patients with Acute Myeloid Leukemia Admitted to Intensive Care Units: Outcome Analysis and Risk Prediction

BACKGROUND: This retrospective, multicenter study aimed to reveal risk predictors for mortality in the intensive care unit (ICU) as well as survival after ICU discharge in patients with acute myeloid leukemia (AML) requiring treatment in the ICU. METHODS AND RESULTS: Multivariate analysis of data fo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pohlen, Michele, Thoennissen, Nils H., Braess, Jan, Thudium, Johannes, Schmid, Christoph, Kochanek, Matthias, Kreuzer, Karl-Anton, Lebiedz, Pia, Görlich, Dennis, Gerth, Hans U., Rohde, Christian, Kessler, Torsten, Müller-Tidow, Carsten, Stelljes, Matthias, Büchner, Thomas, Schlimok, Günter, Hallek, Michael, Waltenberger, Johannes, Hiddemann, Wolfgang, Berdel, Wolfgang E., Heilmeier, Bernhard, Krug, Utz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5004890/ https://www.ncbi.nlm.nih.gov/pubmed/27575819 http://dx.doi.org/10.1371/journal.pone.0160871

Ejemplares similares

Correction: Patients with Acute Myeloid Leukemia Admitted to Intensive Care Units: Outcome Analysis and Risk Prediction
por: Pohlen, Michele, et al.
Publicado: (2018)

Identification of the Adapter Molecule MTSS1 as a Potential Oncogene-Specific Tumor Suppressor in Acute Myeloid Leukemia
por: Schemionek, Mirle, et al.
Publicado: (2015)

Outcome of elderly patients with acute promyelocytic leukemia: results of the German Acute Myeloid Leukemia Cooperative Group
por: Lengfelder, Eva, et al.
Publicado: (2012)

Impact of High-Cut-Off Dialysis on Renal Recovery in Dialysis-Dependent Multiple Myeloma Patients: Results from a Case-Control Study
por: Gerth, Hans U., et al.
Publicado: (2016)

Feasibility of Azacitidine Added to Standard Chemotherapy in Older Patients with Acute Myeloid Leukemia — A Randomised SAL Pilot Study
por: Krug, Utz, et al.
Publicado: (2012)

Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia
por: Rausch, Christian, et al.
Publicado: (2023)

P457: COMPLEX CARYOTYPE IS AN INDEPENDENT RISK FACTOR IN TP53-MUTATED AML
por: Rausch, Christian, et al.
Publicado: (2023)

P434: MYELODYSPLASIA-RELATED MUTATIONS IN THE NEW ELN CLASSIFICATION: DOES CLONAL SIZE PLAY A ROLE?
por: Rausch, Christian, et al.
Publicado: (2023)

The NPM1 Mutation Type Has No Impact on Survival in Cytogenetically Normal AML
por: Pastore, Friederike, et al.
Publicado: (2014)

P446: COMPREHENSIVE CHARACTERIZATION OF DIFFERENTIAL GENE EXPRESSION AND ISOFORM USAGE IN SPLICING FACTOR-MUTATED ACUTE MYELOID LEUKEMIA USING LONG-READ SEQUENCING
por: Thieme, Susanne, et al.
Publicado: (2023)

Erufosine, a novel alkylphosphocholine, in acute myeloid leukemia: single activity and combination with other antileukemic drugs
por: Fiegl, Michael, et al.
Publicado: (2007)

A clinically applicable gene expression–based score predicts resistance to induction treatment in acute myeloid leukemia
por: Moser, Christian, et al.
Publicado: (2021)

Workflow to improve patient recruitment for clinical trials within hospital information systems – a case-study
por: Dugas, Martin, et al.
Publicado: (2008)

Prediction of complete remission and survival in acute myeloid leukemia using supervised machine learning
por: Eckardt, Jan-Niklas, et al.
Publicado: (2022)

Unsupervised meta-clustering identifies risk clusters in acute myeloid leukemia based on clinical and genetic profiles
por: Eckardt, Jan-Niklas, et al.
Publicado: (2023)

Genetics of acute myeloid leukemia in the elderly: mutation spectrum and clinical impact in intensively treated patients aged 75 years or older
por: Prassek, Victoria V., et al.
Publicado: (2018)

Germline SNPs previously implicated as prognostic biomarkers do not associate with outcomes in intensively treated AML
por: Batcha, Aarif M. N., et al.
Publicado: (2022)

Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation
por: Kunadt, Desiree, et al.
Publicado: (2022)

Amsacrine-based induction therapy in AML patients with cardiac comorbidities: a retrospective single-center analysis
por: Kuron, David, et al.
Publicado: (2023)

Long-term follow-up of cytogenetically normal CEBPA-mutated AML
por: Pastore, Friederike, et al.
Publicado: (2014)

Integrated RNAi screening identifies the NEDDylation pathway as a synergistic partner of azacytidine in acute myeloid leukemia
por: Klosner, Justine, et al.
Publicado: (2021)

Complete durable remission of a fulminant primary cutaneous aggressive epidermotropic CD8(+) cytotoxic T-cell lymphoma after autologous and allogeneic hematopoietic stem cell transplantation
por: Plachouri, Kerasia-Maria, et al.
Publicado: (2017)

Magnesium levels and outcome after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia
por: Angenendt, Linus, et al.
Publicado: (2020)

Mutations of the EPHB6 Receptor Tyrosine Kinase Induce a Pro-Metastatic Phenotype in Non-Small Cell Lung Cancer
por: Bulk, Etmar, et al.
Publicado: (2012)

Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia
por: Herold, Tobias, et al.
Publicado: (2020)

Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia – implications for the European LeukemiaNet risk classification
por: Eckardt, Jan-Niklas, et al.
Publicado: (2023)

The role of autologous stem cell transplantation (ASCT) in aggressive B-cell lymphomas: real-world data from a retrospective single-center analysis
por: Wullenkord, Ramona, et al.
Publicado: (2021)

Long-term survival and polyclonal immunoglobulin reconstitution after allogeneic stem cell transplantation in multiple myeloma
por: Eisfeld, Christine, et al.
Publicado: (2020)

A Phase I Dose Escalation Study of the Triple Angiokinase Inhibitor Nintedanib Combined with Low-Dose Cytarabine in Elderly Patients with Acute Myeloid Leukemia
por: Schliemann, Christoph, et al.
Publicado: (2016)

Potential therapeutic impact of CD13 expression in non-small cell lung cancer
por: Schmidt, Lars Henning, et al.
Publicado: (2017)

Correction: Potential therapeutic impact of CD13 expression in non-small cell lung cancer
por: Schmidt, Lars Henning, et al.
Publicado: (2017)

Molecular adsorbent recirculating system (MARS) in acute liver injury and graft dysfunction: Results from a case-control study
por: Gerth, Hans U., et al.
Publicado: (2017)

Activating FLT3 Mutants Show Distinct Gain-of-Function Phenotypes In Vitro and a Characteristic Signaling Pathway Profile Associated with Prognosis in Acute Myeloid Leukemia
por: Janke, Hanna, et al.
Publicado: (2014)

Clonal heterogeneity of FLT3-ITD detected by high-throughput amplicon sequencing correlates with adverse prognosis in acute myeloid leukemia
por: Schranz, Katrin, et al.
Publicado: (2018)

CCC meets ICU: Redefining the role of critical care of cancer patients
por: von Bergwelt-Baildon, Michael, et al.
Publicado: (2010)

Using stroma-anchoring cytokines to augment ADCC: a phase 1 trial of F16IL2 and BI 836858 for posttransplant AML relapse
por: Berdel, Andrew F., et al.
Publicado: (2022)

Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study
por: Middeke, Jan M., et al.
Publicado: (2022)

Robust Optimal Design of Experiments for Model Discrimination Using an Interactive Software Tool
por: Stegmaier, Johannes, et al.
Publicado: (2013)

Rapid amelioration of respiratory parameters in severely obese patients after percutaneous dilatational tracheotomy
por: Kaese, S, et al.
Publicado: (2015)

The clinical mutatome of core binding factor leukemia
por: Opatz, Sabrina, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_urokea9cddbmo6hct68stvs64e